Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Chronic Heart Failure

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 56 articles: HTML format

Single Articles

March 2023
1. HOUSTON BA, Brittain EL, Tedford RJ
   Right Ventricular Failure.
   N Engl J Med. 2023;388:1111-1125.
   PubMed    
   
   
   January 2023
2. SOLOMON SD, Vaduganathan M, McMurray JJV
   Dapagliflozin in Heart Failure with Preserved Ejection Fraction. Reply.
   N Engl J Med. 2023;388:288.
   PubMed    
   
   
   
3. GABRIELLI D, Oliva F, Zuccala G
   Dapagliflozin in Heart Failure with Preserved Ejection Fraction.
   N Engl J Med. 2023;388:287-288.
   PubMed    
   
   
   
4. WEIR RAP
   Dapagliflozin in Heart Failure with Preserved Ejection Fraction.
   N Engl J Med. 2023;388:287.
   PubMed    
   
   
   
5. REDFORS B, Omerovic E
   Dapagliflozin in Heart Failure with Preserved Ejection Fraction.
   N Engl J Med. 2023;388:286-287.
   PubMed    
   
   
   
6. ZWECK E, Westenfeld R
   Dapagliflozin in Heart Failure with Preserved Ejection Fraction.
   N Engl J Med. 2023;388:286.
   PubMed    
   
   
   
7. GOYAL P, Horn EM
   More COACHing Needed to Optimize Care after Heart Failure Hospitalization.
   N Engl J Med. 2023;388:82-83.
   PubMed    
   
   
   December 2022
8. MULLENS W, Martens P
   Acute Decompensated Heart Failure, Volume, and Acetazolamide. Reply.
   N Engl J Med. 2022;387:2487.
   PubMed    
   
   
   
9. FAUCHIER L, Maisons V, Halimi JM
   Acute Decompensated Heart Failure, Volume, and Acetazolamide.
   N Engl J Med. 2022;387:2486-2487.
   PubMed    
   
   
   
10. KAPELIOS CJ, Drakos SG, Fang JC
    Acute Decompensated Heart Failure, Volume, and Acetazolamide.
    N Engl J Med. 2022;387:2486.
    PubMed    
    
    
    
11. CULIC V
    Acute Decompensated Heart Failure, Volume, and Acetazolamide.
    N Engl J Med. 2022;387:2485-2486.
    PubMed    
    
    
    November 2022
12. LEE DS, Straus SE, Farkouh ME, Austin PC, et al
    Trial of an Intervention to Improve Acute Heart Failure Outcomes.
    N Engl J Med. 2022 Nov 5. doi: 10.1056/NEJMoa2211680.
    PubMed     Abstract available
    
    
    October 2022
13. PERERA D, Clayton T, O'Kane PD, Greenwood JP, et al
    Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction.
    N Engl J Med. 2022;387:1351-1360.
    PubMed     Abstract available
    
    
    
14. KIRTANE AJ
    REVIVE-ing a Weak Heart - Details Matter.
    N Engl J Med. 2022;387:1426-1427.
    PubMed    
    
    
    September 2022
15. NATHAN DM, Lachin JM, Bebu I, Burch HB, et al
    Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    N Engl J Med. 2022;387:1075-1088.
    PubMed     Abstract available
    
    
    August 2022
16. FELKER GM
    New Decongestion Strategies in an Evolving Heart Failure Landscape.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMe2209997.
    PubMed    
    
    
    
17. SOLOMON SD, McMurray JJV, Claggett B, de Boer RA, et al
    Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMoa2206286.
    PubMed     Abstract available
    
    
    
18. MARGULIES KB
    DELIVERing Progress in Heart Failure with Preserved Ejection Fraction.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMe2210177.
    PubMed    
    
    
    
19. MULLENS W, Dauw J, Martens P, Verbrugge FH, et al
    Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMoa2203094.
    PubMed     Abstract available
    
    
    May 2022
20. ANKER SD, Butler J, Packer M
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply.
    N Engl J Med. 2022;386:e57.
    PubMed    
    
    
    
21. HEERSPINK HJL, Inker L, Greene T
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    N Engl J Med. 2022;386:e57.
    PubMed    
    
    
    
22. AMATO J JR
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    N Engl J Med. 2022;386:e57.
    PubMed    
    
    
    
23. TRIPOSKIADIS FK, Xanthopoulos A, Iliodromitis EK
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    N Engl J Med. 2022;386:e57.
    PubMed    
    
    
    
24. BHATTACHARYYA D, Kar A, Dhumale S
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    N Engl J Med. 2022;386:e57.
    PubMed    
    
    
    November 2021
25. PFEFFER MA, Claggett B, Lewis EF, Granger CB, et al
    Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    N Engl J Med. 2021;385:1845-1855.
    PubMed     Abstract available
    
    
    September 2021
26. KITZMAN DW, Pastva AM, Mentz RJ
    Physical Rehabilitation in Patients with Heart Failure. Reply.
    N Engl J Med. 2021;385:1340-1341.
    PubMed    
    
    
    
27. DUPONT J, Koppo K, Gielen E
    Physical Rehabilitation in Patients with Heart Failure.
    N Engl J Med. 2021;385:1340.
    PubMed    
    
    
    
28. SCHUTTLER D, Weckbach LT, Brunner S
    Physical Rehabilitation in Patients with Heart Failure.
    N Engl J Med. 2021;385:1339-1340.
    PubMed    
    
    
    
29. FRUSH BW
    Cool Water.
    N Engl J Med. 2021;385:1254-1255.
    PubMed    
    
    
    August 2021
30. ANKER SD, Butler J, Filippatos G, Ferreira JP, et al
    Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    N Engl J Med. 2021 Aug 27. doi: 10.1056/NEJMoa2107038.
    PubMed     Abstract available
    
    
    
31. DRAZNER MH
    SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction - A Win against a Formidable Foe.
    N Engl J Med. 2021 Aug 27. doi: 10.1056/NEJMe2113008.
    PubMed    
    
    
    
32. PACKER M, Butler J, Zannad F, Pocock SJ, et al
    Empagliflozin and Major Renal Outcomes in Heart Failure.
    N Engl J Med. 2021 Aug 27. doi: 10.1056/NEJMc2112411.
    PubMed    
    
    
    
33. JOYNT MADDOX KE, Orav EJ, Zheng J, Epstein AM, et al
    Year 1 of the Bundled Payments for Care Improvement-Advanced Model.
    N Engl J Med. 2021;385:618-627.
    PubMed     Abstract available
    
    
    May 2021
34. TEERLINK JR, Felker GM, McMurray JJV
    Omecamtiv Mecarbil in Systolic Heart Failure. Reply.
    N Engl J Med. 2021;384:1967-1968.
    PubMed    
    
    
    
35. BELLUMKONDA L
    Omecamtiv Mecarbil in Systolic Heart Failure.
    N Engl J Med. 2021;384:1967.
    PubMed    
    
    
    
36. BONAPACE S, Molon G
    Omecamtiv Mecarbil in Systolic Heart Failure.
    N Engl J Med. 2021;384:1967.
    PubMed    
    
    
    
37. KOMAMURA K
    Omecamtiv Mecarbil in Systolic Heart Failure.
    N Engl J Med. 2021;384:1966-1967.
    PubMed    
    
    
    
38. YEKU OO, Medford AJ, Fenves AZ, Uljon SN, et al
    Case 15-2021: A 76-Year-Old Woman with Nausea, Diarrhea, and Acute Kidney Failure.
    N Engl J Med. 2021;384:1943-1950.
    PubMed    
    
    
    
39. ANKER SD, Coats AJS
    Exercise for Frail, Elderly Patients with Acute Heart Failure - A Strong Step Forward.
    N Engl J Med. 2021 May 16. doi: 10.1056/NEJMe2106140.
    PubMed    
    
    
    
40. KITZMAN DW, Whellan DJ, Duncan P, Pastva AM, et al
    Physical Rehabilitation for Older Patients Hospitalized for Heart Failure.
    N Engl J Med. 2021 May 16. doi: 10.1056/NEJMoa2026141.
    PubMed     Abstract available
    
    
    April 2021
41. LEE TH
    Zoom Family Meeting.
    N Engl J Med. 2021;384:1586-1587.
    PubMed    
    
    
    January 2021
42. PACKER M, Zannad F
    Empagliflozin in Heart Failure. Reply.
    N Engl J Med. 2021;384:387-388.
    PubMed    
    
    
    
43. KUMAR S, Sinha S
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:387.
    PubMed    
    
    
    
44. GERARD AO, Favre G, Esnault VLM
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:386-387.
    PubMed    
    
    
    
45. SHANMUGANATHAN M, Goswami RM
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:386.
    PubMed    
    
    
    
46. BHATTACHARYYA D, Kar A
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:385-386.
    PubMed    
    
    
    
47. FAUCHIER L, Fauchier G, Angoulvant D
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:385.
    PubMed    
    
    
    
48. LIN X, Wang S, Huang J
    Empagliflozin in Heart Failure.
    N Engl J Med. 2021;384:384-385.
    PubMed    
    
    
    
49. SWEDBERG K
    Stimulation of Contractility in Systolic Heart Failure.
    N Engl J Med. 2021;384:178-179.
    PubMed    
    
    
    
50. RUDDER M, Russo M, Ventetuolo CE
    Breathing for Two.
    N Engl J Med. 2021;384:61-68.
    PubMed    
    
    
    November 2020
51. BHATT DL, Szarek M, Steg PG, Cannon CP, et al
    Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
    N Engl J Med. 2020 Nov 16. doi: 10.1056/NEJMoa2030183.
    PubMed     Abstract available
    
    
    
52. TEERLINK JR, Diaz R, Felker GM, McMurray JJV, et al
    Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
    N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2025797.
    PubMed     Abstract available
    
    
    October 2020
53. ARMSTRONG PW, Anstrom KJ, O'Connor CM
    Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply.
    N Engl J Med. 2020;383:1497-1498.
    PubMed    
    
    
    
54. RYAN JJ, Maron BA
    Vericiguat in Heart Failure with Reduced Ejection Fraction.
    N Engl J Med. 2020;383:1497.
    PubMed    
    
    
    
55. WEARDEN J, Hough A, Kaiser S
    Vericiguat in Heart Failure with Reduced Ejection Fraction.
    N Engl J Med. 2020;383:1496-1497.
    PubMed    
    
    
    August 2020
56. KIRCHHOF P, Camm AJ, Goette A, Brandes A, et al
    Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.
    N Engl J Med. 2020 Aug 29. doi: 10.1056/NEJMoa2019422.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: